SCHEMBL3536232

SCHEMBL3536232

CC1CCN(c2cc(C3CCN(CC(F)(F)F)CC3)ccc2N)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.45
MEN1 O00255 1/20 0.45
USP2 O75604 1/20 0.45
KMT2A Q03164 1/20 0.45
TLR9 Q9NR96 3/20 0.40
TLR8 Q9NR97 3/20 0.40
TLR7 Q9NYK1 3/20 0.40
ALDH1A1 P00352 2/20 0.39
HTT P42858 1/20 0.39
KDM4E B2RXH2 2/20 0.38
POLB P06746 1/20 0.38
NR4A1 P22736 1/20 0.38
HSD17B10 Q99714 1/20 0.38
DRD2 P14416 2/20 0.37
NPC1 O15118 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
RAB9A P51151 1/20 0.36
CSF1R P07333 2/20 0.36
DCPS Q96C86 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3536228 0.83 ALDH1A1 (0.43) GAAKMT2ATLR9TLR8TLR7
SCHEMBL17397707 0.80 TLR9 (0.47) GAATLR9TLR8TLR7DRD2
SCHEMBL3542138 0.77 CSF1R (0.52) GAAMEN1USP2KMT2AALDH1A1
SCHEMBL27691389 0.76 GAA (0.51) GAAMEN1USP2KMT2AALDH1A1
SCHEMBL3541924 0.76 CSF1R (0.57) GAAMEN1USP2KMT2AALDH1A1
SCHEMBL3538074 0.75 GAA (0.49) GAAMEN1USP2KMT2AALDH1A1
SCHEMBL3542681 0.74 CSF1R (0.44) GAAMEN1USP2KMT2ATLR9
SCHEMBL3533703 0.74 NAMPT (0.47) GAAALDH1A1KDM4EPOLBNR4A1
SCHEMBL1477035 0.73 KDM1A (0.46) TLR9TLR8TLR7DRD2DCPS
SCHEMBL3543343 0.73 NPC1 (0.44) GAAMEN1USP2KMT2ATLR9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US claimed
EP-1807407-B1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2009-07-29 EP claimed
US-20060100201-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-11 US claimed
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US disclosed
EP-1807407-B1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2009-07-29 EP disclosed
US-20060100201-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100201-A1 Inhibitors of c-fms kinase MUSK, FLT3, FES GAA 3696/4885MEN1 731/4885USP2 1200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.